Abstract
The dose-response of serum prolactin (PRL) values to different doses of naloxone (NAL) in rats is bellshaped. To test the effect of different doses of NAL on serum FSH, LH and PRL in humans these hormones were measured in 4 male volunteers after subject blind infusion of 0.02, 0.2 and 0.5 mg/kg NAL in random order. A saline infusion served as control. On each occasion an adjusted volume of 100 ml was infused within 10 min via an antecubital vein. Consequently blood samples were taken every 15 min for 4 h. To compare the response to the different treatments for each hormone the average of an individual’s hormone values (4×16) was set to 100%. Values at each timepoint were expressed in relation to the volunteer’s mean. The means and SE of hormone values set to 100% were: LH = 5.7 ± 0.7 ng/ml; FSH = 3.1 ± 1.0 ng/ml and PRL = 186 + 37 μU/ml. NAL infusion did not affect FSH levels at any dose level. No overall effect of NAL on PRL levels was detectable. There was a significant difference in LH values between saline control and NAL infusions, although no significant difference could be detected between different doses of NAL. Higher doses of NAL merely sustained LH levels for a longer time period. Based on the data presented a short test is suggested for screening patients under different pathophysiological conditions for involvement of endogenous opioids in the regulation of LH secretion.
Similar content being viewed by others
References
Bruni J.F., Van Vugt D., Marshall S., Meites J. Effects of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone. Life Sci. 21: 461, 1977.
Janowsky D., Judd L., Huey L, Roitman N., Parker D. Naloxone effects on serum growth hormone and prolac tin in man. Psychopharmacol. 65: 95, 1979.
Rubin P., Swezey S., Blaschke T. Naloxone lowers plasma prolactin in man. Lancet 1: 1293, 1979.
Morley J.E., Baranetsky N.G., Wingert T.D., Carlson H.E., Hershman J.M., Melmed S., Levin S.R., Jamison K.R., Weitzman R., Chang R.J., Varner A.A. Endocrine effects of Naloxone-induced opiate receptor blockade. J. Clin. Endocrinol. Metab. 50: 251, 1980.
Blankstein J., Reyes F.I., Winter J.S.D., Faiman C. Endorphins and the regulation of the human menstrual cycle. Clin. Endocrinol. (Oxf.) 14: 287, 1981.
Grossman A., Moult P.J.A., Gaillard R.C., Delitala G., Toff W.D., Rees L.H., Besser G.M. The opioid control of LH and FSH release: Effects of a met-enkephalin analogue and naloxone. Clin. Endocrinol. (Oxf.) 74: 41, 1981.
Lightman S.L., Jacobs H.S., Maguire A.K., McGarrick G., Jeffcoate S.L. Constancy of opioid control of luteinizing hormone in different pathophysiological states. J. Clin. Endocrinol. Metab. 52: 1260, 1981.
Shaar C.J., Frederickson R.C.A., Dininger N.B., Jackson L. Enkephalin analogues and naloxone modulate the release of growth hormone and prolactin evidence for regulation by an endogenous opioid peptide in brain. Life Sci 27: 853, 1977.
Keppel G. Design and analysis, ed. 2. Prentice-Hall, Englewood Cliffs, 1982.
SPSS User’s Guide McGraw-Hill, New York, 1983.
Grossman A., Rees L.H. The neuroendocrinology of opioid peptides. Br. Med. Bull., 39: 83, 1983.
Moult P. J. A., Grossman A., Evans J.M., Rees L.H., Besser G.M. The effect of naloxone on pulsatile gonadotrophin release in normal subjects. Clin. Endocrinol. (Oxf.) 14: 321, 1981.
Grossman A. Brain opiates and neuroendocrine function. Clin. Endocrinol. Metab. 12: 725, 1983.
Berkowitz B.A., Ngai S.H., Hempstead J., Spector S. Disposition of naloxone: Use of a new radioimmunoas say. J. Pharmacol. Exp. Ther. 195: 499, 1975.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Knuth, U.A., Nieschlag, E. Effect of different doses of naloxone on serum levels of prolactin and gonadotropins in young male volunteers. J Endocrinol Invest 8, 55–57 (1985). https://doi.org/10.1007/BF03350640
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350640